Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Your ultimate guide to the 2024 North Carolina State Fair
Recommended
North Carolina Voter Guide 2024: Who's running, how, where, when to vote in NC election
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
52.61
+0.33 (+0.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
901,442
Open
52.20
Bid (Size)
52.60 (2)
Ask (Size)
54.01 (1)
Prev. Close
52.28
Today's Range
52.20 - 53.09
52wk Range
32.83 - 65.53
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
October 11, 2024
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via
Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
October 10, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
Performance
YTD
+40.71%
+40.71%
1 Month
-11.58%
-11.58%
3 Month
-3.18%
-3.18%
6 Month
+35.91%
+35.91%
1 Year
+49.63%
+49.63%
More News
Read More
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
October 04, 2024
Via
Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
September 19, 2024
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
September 19, 2024
Via
Chartmill
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
September 13, 2024
Via
Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
August 29, 2024
Via
Chartmill
Top 2 Health Care Stocks That May Plunge In August
August 26, 2024
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
September 13, 2024
Via
Chartmill
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
September 13, 2024
Via
Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
August 28, 2024
Via
Chartmill
How Is The Market Feeling About Halozyme Therapeutics?
August 20, 2024
Via
Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
Via
Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
August 01, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
August 08, 2024
Via
Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
August 08, 2024
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
August 06, 2024
Via
Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
Via
Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
August 05, 2024
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
August 04, 2024
Via
InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.